Quick Answer
HCW Biologics Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
HCW Biologics Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $7.38M | +17.0% |
| 2023 | $6.30M | -1.6% |
| 2022 | $6.41M | — |
| 2021 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | -100.0% |
| June 30, 2025 | $367.2K | -96.3% | -95.2% |
| March 31, 2025 | $7.71M | -6.9% | +4.4% |
| December 31, 2024 | $7.38M | +17.0% | +14.2% |
| September 30, 2024 | $6.46M | +2.1% | -34.7% |
| June 30, 2024 | $9.90M | +55.7% | +19.7% |
| March 31, 2024 | $8.27M | +29.6% | +31.3% |
| December 31, 2023 | $6.30M | -1.6% | -0.4% |
- HCW Biologics Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from HCW Biologics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: